menu
    • menu

    Company profile for Superluminal Medicines

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Superluminal MedicinesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Berkeley St, 18th Floor, Boston, MA 02116
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://superluminalrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/superluminalrx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly Signs $1.3 B Deal with Superluminal for Obesity Medicines
    Lilly Signs $1.3 B Deal with Superluminal for Obesity Medicines

    15 Aug 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-signs-13-billion-deal-with-superluminal-discover-obesity-medicines-using-2025-08-14/

    REUTERS
    15 Aug 2025
    Share Share
    Superluminal’s MC4R Agonist Advances for Treatment of Obesity
    Superluminal’s MC4R Agonist Advances for Treatment of Obesity

    22 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/superluminal-medicines-announces-a-selective-biased-mc4r-agonist-is-advancing-to-ind-enabling-studies-for-the-treatment-of-obesity-302510239.html

    PR NEWSWIRE
    22 Jul 2025
    Share Share
    Axcelead, Superluminal to Collaborate on Drug Discovery
    Axcelead, Superluminal to Collaborate on Drug Discovery

    23 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250623762266/en/Axcelead-DDP-and-Superluminal-Announce-the-Intent-to-Collaborate-on-Drug-Discovery-Targeting-Specific-Molecular-Mechanisms-continuing-a-productive-relationship

    BUSINESSWIRE
    23 Jun 2025
    Share Share
    Superluminal Medicines Forms Scientific Advisory Board
    Superluminal Medicines Forms Scientific Advisory Board

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2955147/0/en/Superluminal-Medicines-Announces-Formation-of-Scientific-Advisory-Board.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Superluminal Medicines Closes $120 Million Series A Round
    Superluminal Medicines Closes $120 Million Series A Round

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942684/0/en/Superluminal-Medicines-Closes-120-Million-Series-A-Round.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    Superluminal Launches with $33 Million Seed Round to Fuel its Drug Discovery
    Superluminal Launches with $33 Million Seed Round to Fuel its Drug Discovery

    28 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/28/2732498/0/en/Superluminal-Medicines-Launches-with-33-Million-Seed-Round-to-Fuel-its-Drug-Discovery-Engine-and-Pipeline-of-Small-Molecule-Therapeutics.html

    GLOBENEWSWIRE
    28 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search